Objective: To quantify the number of French aPD patients initiating continuous delivery of LCIG from 2013 to 2017 and to describe their demographic, clinical and therapeutic features.

Background: Available data on French aPD patients characteristics, especially those under LCIG, are very limited.

Method: POMPE-PARK study was designed as a non-interventional retrospective longitudinal study on data from the French national health insurance database (SNDS) that covers approximately 99% of the French population. Patient selection was based on outpatient reimbursed expenditures between January 1, 2013 and December 31, 2017. LCIG population was made up of all adult aPD patients initiating LCIG therapy from 2013 to 2017. Patients were followed up over a maximal period of 2 years.

Results: LCIG population included 310 patients from 2013 to 2017. The annual number of aPD patients initiating LCIG increased from 13 in 2013 to 106 in 2017. At the time of the first LCIG delivery (‘index date’), 55.5% were men; 68.1% aged ≥65. Within a 3-year period before ‘index date’, the Charlson comorbidity index was 3.6 (median); 56.3% had history of PD identified as  a Long Duration Disease >10 years; 95.1% suffered from at least one condition of interest, such as psychiatric disorders (75.4%), dystonia (59.3%), walking disability (55.8%) and hallucinations (46.4%); 14.8% underwent deep brain stimulation prior to LCIG initiation; 97.7% received PD treatment: levodopa (97.4%), dopamine agonist (79.0%) and MAOIs (45.1%).
 95.8% were treated for non-motor symptoms, mainly psychotropic drugs (91.6%): anxiolytics (69.6%), antidepressants (68.0%) and hypnotic/sedative drugs (44.8%). Within a 2-year period after ‘index date’, LCIG treatment was discontinued in 31.5% of patients after 731 days of treatment (median).  The mean daily dose was 1997.3 mg. Most patients (79.3%) used at least one cassette/day. Consumption of hospital care increased during the exposition period, mainly due to device-related issues.

Conclusion: This study provides descriptive data on French aPD patients initiating LCIG in real-life practice (2013-2017). Despite severe impairment with multiple symptomatic treatments, 68.5% patients continued LCIG treatment after 2 years.

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/overview-of-the-population-of-patients-with-advanced-parkinsons-disease-apd-initiating-therapy-with-levodopa-carbidopa-intestinal-gel-lcig-pompe-park-study-on-french-health-insurance-dat/